Newspaper wrap-up: American Capital Strategies tied to Baxter’s Heparin generic problems

MAJOR PAPERS:

  • The Wall Street Journal reported that the focus of reports of four deaths and 350 allergic reactions to Baxter worldly Inc’s (NYSE: BAX) generic version of the blood thinner drug Heparin, and the ingredients supplied by a Chinese manufacturer, plus includes Wisconsin-based Scientific Protein Laboratories, a co-owner of the Chinese manufacturing plant, and majority owned by American Capital Strategies Ltd (NASDAQ: ACAS), a Maryland buyout firm.
  • Citigroup Incorporated (NYSE: C) has suspended investors at its CSO Partners hedge fund from withdrawing their money after they attempted to pull more than 30% of the
    fund’s nearly $500M in assets, the Wall Street Journal reported.
  • AT&T Inc (NYSE: T) is seeking more revenue from India as it tries to expand its consumer mobile phone operations external the U.S, the Financial Times reported.

OTHER PAPERS:

  • According to the New York Times, the FDA broke its own rules by approving for sale Baxter International’s Heparin without first inspecting a Chinese plant where the drug’s key ingredient is made.

Original post by Laurie Pasternack

credit investing mortgage debt credit report student loans credit repair credit card student loan consolidation tax

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • StumbleUpon
  • Fark
  • blinkbits
  • BlinkList
  • blogmarks
  • Furl
  • Netscape
  • NewsVine
  • Reddit
  • Spurl
  • Technorati
  • YahooMyWeb
Related Articles
  • China quality problems may form Baxter (BAX) the next Mattel (MAT)
  • Newspaper wrap-up: Investigated ingredient in Baxter’s generic heparin drug made in China
  • American Capital Strategies searches for targets that are ripe for change
  • Teva sees strong generic growth
  • Option update: MetLife (MET), American Capital (ACAS) volatility up
  • No comments yet. Be the first.

    Leave a reply